BMY Targets Real-World Edge for Ozanimod in Ulcerative Colitis
at www.tipranks.com (Fri, 13-Mar 12:32 PM)
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY)
at www.tipranks.com (Fri, 13-Mar 5:50 AM)
Bristol Myers Squibb's Phase 3 Mezigdomide Study Delivers First Positive Results in Refractory Multiple Myeloma
Market Chameleon (Mon, 9-Mar 7:12 AM)
Bristol Myers Squibb’s 2025 Financial Results Drop: What Investors Need to Know Ahead of Today’s Conference Call
Market Chameleon (Thu, 5-Feb 7:44 AM)
